Original Article

You have full text access to this OnlineOpen article

The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module

EORTC QLQ-CX24†

  1. Elfriede R. Greimel PhD1,‡,*,
  2. Karin Kuljanic Vlasic MA2,
  3. Ann-Charlotte Waldenstrom MD3,
  4. Vlatka M. Duric PhD4,
  5. Pernille T. Jensen MD, PhD5,
  6. Susanne Singer PhD6,
  7. Weichu Chie MD, PhD7,
  8. Andy Nordin MBBS8,
  9. Vesna Bjelic Radisic MD1,
  10. Dariusz Wydra MD, PhD9,
  11. on behalf of the European Organization for Research and Treatment of Cancer Quality-of-Life Group§

Article first published online: 14 SEP 2006

DOI: 10.1002/cncr.22217

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1812–1822, 15 October 2006

Additional Information

How to Cite

Greimel, E. R., Kuljanic Vlasic, K., Waldenstrom, A.-C., Duric, V. M., Jensen, P. T., Singer, S., Chie, W., Nordin, A., Bjelic Radisic, V., Wydra, D. and on behalf of the European Organization for Research and Treatment of Cancer Quality-of-Life Group (2006), The European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire cervical cancer module. Cancer, 107: 1812–1822. doi: 10.1002/cncr.22217

Author Information

  1. 1

    Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria

  2. 2

    Department of Gynecology and Obstetrics, University Hospital Center Rijeka, Rijeka, Croatia

  3. 3

    Department of Oncology, Sahlgrenska University Hospital, Goteborg, Sweden

  4. 4

    National Health and Medical Research Council Clinical Trials Centre, University of Sydney and Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, New South Wales, Australia

  5. 5

    Department of Obstetrics and Gynecology, Herlev University Hospital, Copenhagen, Denmark

  6. 6

    Department of Social Medicine, University of Leipzig, Leipzig, Germany

  7. 7

    Department of Public Health and Institute of Preventative Medicine, National Taiwan University, Taipei, Taiwan

  8. 8

    East Kent Gynaecological Oncology Centre, Queen Elizabeth the Queen Mother Hospital, Margate, United Kingdom

  9. 9

    Department of Gynecology, Medical University of Gdansk, Gdansk, Poland

  1. ‡

    Fax: 011 (43) 3163853061.

  2. §

    The following are members of the EORTC Gynecological Cancer Group Steering Committee: K. Bergmark (Sweden), C. Creutzberg (the Netherlands), B. DeSouza (Brazil), F. Fehlauer (Germany), L. Incrocci (The Netherlands), J. Routledge (U.K.), T. Swift (U.K.), and H. Y. Yun (Korea).

*Department of Obstetrics and Gynecology, Medical University Graz, Auenbruggerplatz 14, 8036 Graz, Austria

  1. †

    The EORTC QLQ-CX24 is copyrighted by the EORTC QoL Group. The module and the scoring procedure are available on request (Andrew Bottomley, PhD, EORTC Quality of Life Unit; E-mail: abo@eortc.be).

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 14 SEP 2006
  3. Manuscript Accepted: 27 JUL 2006
  4. Manuscript Revised: 25 JUL 2006
  5. Manuscript Received: 5 APR 2006

Funded by

  • European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Group
  • National Science Council, Taiwan. Grant Number: (NSC 93-2320-B0002-072, NSC 94-2314-B-00 2-098)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (132K)

Keywords:

  • quality of life;
  • patient-reported outcome;
  • questionnaire development;
  • European Organ for Research and Treatment of Cancer;
  • reliability;
  • validity;
  • cervical cancer

Abstract

BACKGROUND

The authors report on the development and validation of a cervical cancer module for the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life (QoL) questionnaire (QLQ), which was designed to assess disease-specific and treatment-specific aspects of QoL in patients with cervical cancer.

METHODS

The cervical cancer module (EORTC QLQ-CX24) was developed in a multicultural, multidisciplinary setting to supplement the EORTC QLQ-C30 core questionnaire. The QLQ-C30 and the cervical cancer module were administered to 346 patients with cervical cancer who underwent radical hysterectomy and received radiotherapy and chemotherapy. Psychometric analyses were performed by using data from 2 independent samples.

RESULTS

The QLQ-CX24 consists of 3 multiitem scales and 5 single-item scales. Multitrait scaling analyses revealed high internal consistencies for the subscales with Cronbach α coefficients ranging from .72 to .87 (Symptom Experience, .72; Body Image, .86; Sexual/Vaginal Functioning, .87). Convergent and discriminant validity were fulfilled with scaling errors below 3%. The QLQ-CX24 was capable of discriminating between clinical subgroups. All items exhibited good compliance with <3% missing values. Most patients completed the EORTC QLQ-C30 and the QLQ-CX24 in <15 minutes (86%), and many did not require any assistance to complete the questionnaires (65%).

CONCLUSIONS

The current psychometric analyses supported the content and construct validity and the reliability of the EORTC QLQ-CX24 module. This newly developed module is a useful instrument for assessing the QoL of patients who are treated for cervical cancer both in clinical trials and in clinical practice. Cancer 2006. © 2006 American Cancer Society.

View Full Article (HTML) Get PDF (132K)